Table 1 Comparison of clinical and molecular characteristics with miR-363 expression in AML patients
Characteristic | Chemotherapy group | Allo-HSCT group | ||||
|---|---|---|---|---|---|---|
High miR-363 (n = 45) | Low miR-363 (n = 45) | P | High miR-363 (n = 36) | Low miR-363 (n = 36) | P | |
Age/years, median | 68 (33–88) | 62 (22–77) | 0.005 | 52 (18–65) | 51 (21–72) | 0.585 |
Age group, n (%), years | 0.006 | 0.793 | ||||
< 60 | 8 (17.8) | 21 (46.7) | 25 (69.4) | 27 (75.0) | ||
≥ 60 | 37 (82.2) | 24 (53.3) | 11 (30.6) | 9 (25.0) | ||
Gender, n (%) | 1.000 | 0.634 | ||||
Male | 25 (55.6) | 25 (55.6) | 22 (55.6) | 19 (52.8) | ||
Female | 20 (44.4) | 20 (44.4) | 14 (38.9) | 17 (47.2) | ||
WBC, × 109/L, median | 8.3 (0.7–171.9) | 39.8 (2.5–298.4) | 0.001 | 11.4 (0.6–77.3) | 35.8 (1.2–223.8) | 0.001 |
BM blast (%), median | 71 (30–98) | 73 (32–99) | 0.580 | 67.5 (30–95) | 71.5 (39–100) | 0.156 |
PB blast (%), median | 16 (0–91) | 52 (0–98) | 0.007 | 33.5 (0–90) | 56 (8–96) | 0.008 |
FAB subtypes, n (%) | ||||||
M0 | 5 (11.1) | 3 (6.7) | 0.714 | 7 (19.4) | 2 (5.6) | 0.151 |
M1 | 9 (20) | 11 (24.4) | 0.800 | 10 (37.8) | 13 (36.1) | 0.614 |
M2 | 10 (22.2) | 11 (24.4) | 1.000 | 9 (25.0) | 10 (27.8) | 1.000 |
M4 | 10 (22.2) | 14 (31.1) | 0.475 | 5 (13.9) | 9 (25.0) | 0.372 |
M5 | 8 (17.8) | 5 (11.1) | 0.550 | 3 (8.3) | 1 (2.8) | 0.614 |
M6 | 2 (4.4) | 1 (2.2) | 1.000 | 1 (2.8) | 0 | 1.000 |
M7 | 1 (2.2) | 0 (0) | 1.000 | 1 (2.8) | 0 | 1.000 |
Others | 1 (2.2) | 0 (0) | 1.000 | 0 | 1 (2.8) | 1.000 |
Karyotype, n (%) | ||||||
Normal | 20 (44.4) | 24 (53.3) | 0.527 | 16 (44.4) | 18 (50.0) | 0.814 |
Complex | 11 (24.4) | 1 (2.2) | 0.004 | 11 (30.6) | 1 (2.8) | 0.003 |
8 Trisomy | 0 | 2 (4.4) | 0.494 | 2 (5.6) | 5 (13.9) | 0.429 |
CBFβ–MYH11 | 0 | 7 (15.6) | 0.012 | 0 | 5 (13.9) | 0.054 |
11q23/MLL | 4 (8.9) | 1 (2.2) | 0.361 | 2 (5.6) | 1 (2.8) | 1.000 |
−7/7q− | 2 (4.4) | 1 (2.2) | 1.000 | 1 (2.8) | 1 (2.8) | 1.000 |
BCR–ABL1 | 1 (2.2) | 0 | 1.000 | 1 (2.8) | 1 (2.8) | 1.000 |
RUNX1–RUNX1T | 1 (2.2) | 5 (11.1) | 0.203 | 0 | 1 (2.8) | 1.000 |
Others | 6 (13.3) | 4 (8.9) | 0.739 | 3 (8.3) | 3 (8.3) | 1.000 |
Risk, n (%) | ||||||
Good | 1 (2.2) | 12 (26.7) | 0.002 | 0 | 6 (16.7) | 0.025 |
Intermediate | 25 (55.6) | 25 (55.6) | 1.000 | 19 (52.8) | 22 (61.1) | 0.634 |
Poor | 18 (40.0) | 7 (15.6) | 0.018 | 17 (47.2) | 7 (19.4) | 0.023 |
Others | 1 (2.2) | 1 (2.2) | 1.000 | 0 | 1 (2.8) | 1.000 |
FLT3–ITD, n (%) | 0.784 | 0.045 | ||||
Presence | 7 (15.6) | 9 (20.0) | 4 (11.1) | 12 (33.3) | ||
Absence | 38 (84.4) | 36 (80.0) | 32 (88.9) | 24 (66.7) | ||
NPM1, n (%) | 0.023 | 0.430 | ||||
Mutation | 9 (20.0) | 20 (44.4) | 8 (22.2) | 12 (33.3) | ||
Wild type | 36 (80.0) | 25 (55.6) | 28 (77.8) | 24 (66.7) | ||
CEBPA, n (%) | ||||||
Single mutation | 1 (2.2) | 2 (4.4) | 1.000 | 0 | 5 (13.9) | 0.054 |
Double mutation | 0 | 0 | 1 (2.8) | 2 (5.6) | 1.000 | |
Wild type | 44 (97.8) | 43 (95.6) | 1.000 | 35 (97.2) | 29 (80.6) | 0.055 |
DNMT3A, n (%) | 1000 | 0.786 | ||||
Mutation | 13 (28.9) | 12 (26.7) | 10 (27.8) | 8 (22.2) | ||
Wild type | 32 (71.1) | 33 (73.3) | 26 (72.2) | 28 (7.8) | ||
IDH1/IDH2, n (%) | 0.167 | 0.415 | ||||
Mutation | 5 (11.1) | 11 (24.4) | 11 (30.6) | 7 (19.4) | ||
Wild type | 40 (88.9) | 34 (75.6) | 25 (69.4) | 29 (80.6) | ||
RUNX1, n (%) | 0.714 | 0.260 | ||||
Mutation | 5 (11.1) | 3 (6.7) | 6 (16.7) | 2 (5.6) | ||
Wild type | 40 (88.9) | 42 (93.3) | 30 (83.3) | 34 (94.4) | ||
MLL–PTD, n (%) | 1.000 | 0.614 | ||||
Presence | 2 (4.4) | 3 (6.7) | 3 (8.3) | 1 (2.8) | ||
Absence | 43 (95.6) | 42 (93.7) | 33 (91.7) | 35 (97.2) | ||
NRAS/KRAS, n (%) | 1.000 | 1.000 | ||||
Mutation | 6 (13.3) | 7 (15.6) | 4 (11.1) | 3 (8.3) | ||
Wild type | 39 (86.7) | 38 (84.4) | 32 (88.9) | 33 (91.7) | ||
TET2, n (%) | 0.118 | 0.614 | ||||
Mutation | 9 (20.0) | 3 (6.7) | 1 (2.8) | 3 (8.3) | ||
Wild type | 36 (80.0) | 42 (93.7) | 35 (97.2) | 33 (91.7) | ||
TP53, n (%) | 0.000 | 0.115 | ||||
Mutation | 11 (24.4) | 0 | 4 (11.1) | 0 | ||
Wild type | 34 (75.6) | 45 (100.0) | 32 (88.9) | 36 (100.0) | ||
Relapse, n (%) | 0.001 | 0.474 | ||||
Yes | 42 (93.3) | 28 (62.2) | 23 (63.9) | 19 (47.2) | ||
No | 3 (6.7) | 17 (37.8) | 13 (36.1) | 17 (52.8) | ||